A Phase 2, Multicenter, Randomized, Double-Blind, Proof of Biology Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

This study is designed to assess the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with systemic sclerosis (SSc). Approximately 45 patients at approximately 40 sites will be randomized in a 2:1 ratio to receive either 10 mg/kg CM-101 or placebo.

开始日期2024-09-01

申办/合作机构

Chemomab Ltd.

EUCTR2019-002945-39-ES

/ Unknown status临床2期

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis - The SPRING study

开始日期2022-01-20

申办/合作机构

Chemomab Ltd.

NCT05824156

/ Completed临床2期

Phase 2A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of CM-101 in Patients With Non-Alcoholic Steatohepatitis (NASH)

This phase 2a study is a multi-center, double-blind randomized, placebo-controlled study. The study is designed to determine the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) patients with stage 1c, 2 or 3 fibrosis. The patients will be randomized to 1 of 2 treatment groups: 5 mg/kg CM-101 or placebo.

开始日期2021-02-24

申办/合作机构

Chemomab Ltd.

100 项与 Chemomab Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Chemomab Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Chemomab Ltd. 相关的文献（医药）

2019-09-01·Annals of the rheumatic diseases1区 · 医学

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

1区 · 医学

Article

作者: Levi, Yair ; Segal Salto, Michal ; Barashi, Neta ; Katav, Avi ; Edelshtein, Victoria ; George, Jacob ; Mor, Adi ; Manetti, Mirko ; Matucci-Cerinic, Marco

Objectives:

We aimed to assess the expression of the CCL24 chemokine in systemic sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3 axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models.

Methods:

We used ELISA and fluorescence immunohistochemistry to determine CCL24 levels in serum and CCL24/CCR3 expression in skin biopsies of SSc patients. Skin fibroblasts and endothelial cells treated with CCL24 or SSc serum with or without CM-101 were used to follow cell activation and differentiation. Prevention and treatment in vivo bleomycin (BLM)-induced models were used to evaluate experimental dermal and pulmonary fibrosis progression following treatment with the CM-101 mAb.

Results:

CCL24 circulating levels were significantly elevated in SSc patients. CCL24/CCR3 expression was strongly increased in SSc skin. Blockade of CCL24 with CM-101 significantly reduced the activation of dermal fibroblasts and their transition to myofibroblasts induced by SSc serum. CM-101 was also able to significantly inhibit endothelial cell activation induced by CCL24. In BLM-induced experimental animal models, CM-101 profoundly inhibited both dermal and pulmonary fibrosis and inflammation.

Conclusions:

CCL24 plays an important role in pathological processes of skin and lung inflammation and fibrosis. Inhibition of CCL24 by CM-101 mAb can be potentially beneficial for therapeutic use in SSc patients.

2018-01-01·Pain research & management3区 · 医学

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

3区 · 医学

ArticleOA

作者: Elkayam, Ori ; Furer, Victoria ; Segal, Michal ; Mor, Adi ; Katav, Avi ; George, Jacob ; Aloush, Valerie ; Hazan, Eyal ; Ablin, Jacob N.

FMS patients demonstrate an altered profile of chemokines relative to healthy controls (HC). Eotaxin-2 is a potent chemoattractant distributed in a variety of tissues. The aim of the study was to compare serum levels of eotaxin-2 between FMS patients and HC and to examine a potential correlation between eotaxin-2 levels and clinical parameters of FMS. Methods. 50 patients with FMS and 15 HC were recruited. Data on the severity of FMS symptoms and depression were collected. Serum levels of eotaxin-2 (ELISA) were determined in all participants. High-sensitive CRP (hs-CRP) was measured in the FMS group. Results. The FMS cohort included predominantly females (84%), mean age of 49, and mean disease duration of 6 years. FMS patients exhibited significantly higher eotaxin-2 levels (pg/ml) versus HC: 833 (±384) versus 622 (±149), p=0.04. Mean hs-CRP level among FMS patients was 4.8 ± 6 mg/l, a value not indicative of acute inflammation. No correlation was found between eotaxin-2 and hs-CRP levels. No correlation was found between eotaxin-2 and severity measures of FMS or depression. Conclusion. Eotaxin-2 does not appear to be a candidate for a disease activity biomarker in FMS. Further research is warranted into the role of this chemokine in the pathophysiology of the FMS.

2013-01-01·World Journal of Cardiovascular Diseases

Anti eotaxin-2 antibodies attenuate the initiation and progression of experimental atherosclerosis

作者: Entin-Meer, Michal ; Mor, Adi ; Afek, Arnon ; Keren, Gad ; George, Jacob

The chemokine eotaxin-2 is a potent chemoattractant for inflammatory cells, the predominants of which are eosinophils.Human and murine atherosclerotic plaques are known to exhibit inflammatory phenotypes where a complex interaction of cytokine and chemokines plays a role.We tested the hypothesis that eotaxin-2 (eo-2) plays a causative role in the initiation and progression of exptl. atherosclerosis.Methods and Results: Sera collected from atherosclerotic ApoE knockout (KO) mice, exhibited significantly higher levels of eo-2 compared to sera collected from their background age matched C57BL/6 litters by ELISA.Moreover, levels of eo-2 were higher in old atherosclerotic ApoE KO mice than in young animals.Similarly, the expression level of the eo-2 receptor, CCR3, was increased in splenocytes of old ApoE compared to the young littermates.Administration of polyclonal blocking antibodies to eotaxin-2 resulted in a significant reduction of early atherosclerotic plaques in ApoE KO mice whereas prolonged treatment of mice with advanced plaques led to atheroma stabilization.A monoclonal antibody (D8) prepared against eo-2 attenuated adhesion of lymphocytes to fibronectin and potently inhibited their migration towards VEGF.Monoclonal blocking antibodies to eo-2 also significantly reduced atherosclerotic plaques in ApoE KO mice.Conclusion: Eo-2 serum levels are elevated in sera of ApoE KO mice with exptl. atherosclerosis and its blockade is associated with reduced fatty streak accumulation and increased plaque stabilization.

项与 Chemomab Ltd. 相关的新闻（医药）

2021-01-27

·GlobeNewswire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, and ALSK Mergers

WILMINGTON, Del., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Anchiano Therapeutics Ltd. (NASDAQ GS: ANCN) regarding possible breaches of fiduciary duties and other violations of law related to Anchiano Therapeutics’ agreement to merge with Chemomab Ltd. To learn more about this investigation and your rights, visit: . Jaws Acquisition Corp. (NYSE: JWS) regarding possible breaches of fiduciary duties and other violations of law related to Jaws Acquisition’s agreement to merge with Cano Health, LLC. To learn more about this investigation and your rights, visit: . GX Acquisition Corp. (NASDAQ GS: GXGX) regarding possible breaches of fiduciary duties and other violations of law related to GX Acquisition’s agreement to merge with Celularity Inc. To learn more about this investigation and your rights, visit: . Alaska Communications Systems Group, Inc. (NASDAQ GS: ALSK) regarding possible breaches of fiduciary duties and other violations of law related to Alaska Communications’ agreement to be acquired by affiliates of ATN International, Inc. and Freedom 3 Capital, LLC. Under the terms of the agreement Alaska Communications’ shareholders will receive $3.40 per share in cash. To learn more about this investigation and your rights, visit: . You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (Toll Free) (302) 295-5310 Fax: (302) 654-7530 info@rl-legal.com

并购

100 项与 Chemomab Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Chemomab Ltd. 相关的转化医学

登录后查看更多信息